Drug use among the elderly with osteoporosis-interpretation on clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update
10.3760/cma.j.issn.0254-9026.2025.02.006
- VernacularTitle:中老年人骨质疏松症药物使用——加拿大《骨质疏松症管理和骨折预防临床实践指南(2023版)》解读
- Author:
Yi ZHOU
1
;
Chen SHI
1
Author Information
1. 华中科技大学同济医学院附属协和医院药学部，武汉 430000
- Publication Type:Journal Article
- Keywords:
Osteoporosis;
Fractures, bone;
Drug therapy
- From:
Chinese Journal of Geriatrics
2025;44(2):141-148
- CountryChina
- Language:Chinese
-
Abstract:
With the aging population in China, the prevalence of osteoporosis and associated fractures is becoming increasingly concerning.In October 2023, the Canadian Osteoporosis Guideline Update Group published the "Clinical Practice Guideline for Management of Osteoporosis and Fracture Prevention in Canada: 2023 Update" , which builds upon the 2010 edition.The primary objective of this guideline is to assist primary healthcare professionals in Canada in screening for osteoporosis and fracture risk factors among middle-aged and elderly individuals residing in the community, as well as to provide interventions aimed at optimizing skeletal health and preventing fractures.This article will focus on interpreting the clinical issues related to exercise, nutritional supplementation, and pharmacological treatment for middle-aged and elderly individuals with osteoporosis as outlined in the new guidelines, integrating key points from the guidelines, evidence-based medical literature, and the latest clinical practices.
